NDAOPHTHALMICSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Clinical Trials (1)
Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl
Started Feb 2022
150 enrolled
Normal Tension GlaucomaPrimary Open-angle GlaucomaGlaucoma, Suspect+1 more
Loss of Exclusivity
LOE Date
Jul 16, 2039
162 months away
Patent Expiry
Jul 16, 2039
Exclusivity Expiry
Sep 22, 2027
Company
ExThera Medical
CA - Martinez